请输入您要查询的百科知识：

　

词条 Congenital disorder of glycosylation
释义

  1. Classification

     Type I  Type II  Disorders of O-mannosylation 

  2. Presentation

  3. N-Glycosylation and known defects

     Type I  Type II 

  4. Diagnosis

  5. Treatment

  6. History

  7. See also

  8. References

  9. External links

{{Infobox medical condition (new)
| name = Congenital disorders of glycosylation
| synonyms =
| image =
| caption =
| pronounce =
| field =
| symptoms =
| complications =
| onset =
| duration =
| types =
| causes =
| risks =
| diagnosis =
| differential =
| prevention =
| treatment =
| medication =
| prognosis =
| frequency =
| deaths =
}}

A congenital disorder of glycosylation (previously called carbohydrate-deficient glycoprotein syndrome) is one of several rare inborn errors of metabolism in which glycosylation of a variety of tissue proteins and/or lipids is deficient or defective. Congenital disorders of glycosylation are sometimes known as CDG syndromes. They often cause serious, sometimes fatal, malfunction of several different organ systems (especially the nervous system, muscles, and intestines) in affected infants. The most common sub-type is PMM2-CDG (formally known as CDG-Ia) where the genetic defect leads to the loss of phosphomannomutase 2 (PMM2), the enzyme responsible for the conversion of mannose-6-phosphate into mannose-1-phosphate.

Classification

Historically, CDGs are classified as Types I and II (CDG-I and CDG-II), depending on the nature and location of the biochemical defect in the metabolic pathway relative to the action of oligosaccharyltransferase. The most commonly used screening method for CDG, analysis of transferrin glycosylation status by isoelectric focusing, ESI-MS, or other techniques, distinguish between these subtypes in so called Type I and Type II patterns.

Currently, twenty-two CDG Type-I and fourteen Type-II subtypes of CDG have been described.[1]

Since 2009, most researchers use a different nomenclature based on the gene defect (e.g. CDG-Ia = PMM2-CDG, CDG-Ib = PMI-CDG, CDG-Ic = ALG6-CDG etc.).[2] The reason for the new nomenclature was the fact that proteins not directly involved in glycan synthesis (such as members of the COG-family[3] and vesicular H+-ATPase [4]) were found to be causing the glycosylation defect in some CDG patients.

Also, defects disturbing other glycosylation pathways than the N-linked one are included in this classification. Examples are the α-dystroglycanopathies (e.g. POMT1/POMT2-CDG (Walker-Warburg syndrome and Muscle-Eye-Brain syndrome)) with deficiencies in O-mannosylation of proteins; O-xylosylglycan synthesis defects (EXT1/EXT2-CDG (hereditary multiple exostoses) and B4GALT7-CDG (Ehlers-Danlos syndrome, progeroid variant)); O-fucosylglycan synthesis (B3GALTL-CDG (Peter’s plus syndrome) and LFNG-CDG (spondylocostal dysostosis III)).

Type I

  • Type I disorders involve disrupted synthesis of the lipid-linked oligosaccharide precursor (LLO) or its transfer to the protein.

Types include:

 ! Type ! OMIM ! Gene ! Locus
Ia (PMM2-CDG)212065}} PMM2 16p13.3-p13.2
Ib (MPI-CDG)602579}} MPI 15q22-qter
Ic (ALG6-CDG)603147}} ALG6 1p22.3
Id (ALG3-CDG)601110}} ALG3 3q27
Ie (DPM1-CDG)608799}} DPM1 20q13.13
If (MPDU1-CDG)609180}} MPDU1 17p13.1-p12
Ig (ALG12-CDG)607143}} ALG12 22q13.33
Ih (ALG8-CDG)608104}} ALG8 11pter-p15.5
Ii (ALG2-CDG)607906}} ALG2 9q22
Ij (DPAGT1-CDG)608093}} DPAGT1 11q23.3
Ik (ALG1-CDG)608540}} ALG1 16p13.3
1L (ALG9-CDG)608776}} ALG9 11q23
Im (DOLK-CDG)610768}} DOLK 9q34.11
In (RFT1-CDG)612015}} RFT1 3p21.1
Io (DPM3-CDG)612937}} DPM3 1q12-q21
Ip (ALG11-CDG)613661}} ALG11 13q14.3
Iq (SRD5A3-CDG)612379}} SRD5A3 4q12
Ir (DDOST-CDG)614507}} DDOST 1p36.12
DPM2-CDGn/a}} DPM2 9q34.13
TUSC3-CDG611093}} TUSC3 8p22
MAGT1-CDG300716}} MAGT1 X21.1
DHDDS-CDG613861}} DHDDS 1p36.11
I/IIx212067}} n/a n/a

Type II

  • Type II disorders involve malfunctioning trimming/processing of the protein-bound oligosaccharide chain.

Types include:

 ! Type ! OMIM ! Gene ! Locus
IIa (MGAT2-CDG)212066}} MGAT2 14q21
IIb (GCS1-CDG)606056}} GCS1 2p13-p12
IIc (SLC335C1-CDG; Leukocyte adhesion deficiency II))266265}} SLC35C1 11p11.2
IId (B4GALT1-CDG)607091}} B4GALT1 9p13
IIe (COG7-CDG)608779}} COG7 16p
IIf (SLC35A1-CDG)603585}} SLC35A1 6q15
IIg (COG1-CDG)611209}} COG1 17q25.1
IIh (COG8-CDG)611182}} COG8 16q22.1
IIi (COG5-CDG)613612}} COG5 7q31
IIj (COG4-CDG)613489}} COG4 16q22.1
IIL (COG6-CDG)n/a}} COG6 13q14.11
ATP6V0A2-CDG (autosomal recessive cutis laxa type 2a (ARCL-2A))219200}} ATP6V0A2 12q24.31
MAN1B1-CDG (Mental retardation, autosomal recessive 15)614202}} MAN1B1 9q34.3
ST3GAL3-CDG (Mental retardation, autosomal recessive 12)611090}} ST3GAL3 1p34.1

Disorders of O-mannosylation

  • Disorders with deficient α-dystroglycan O-mannosylation.

Mutations in several genes have been associated with the traditional clinical syndromes, termed muscular dystrophy-dystroglycanopathies (MDDG). A new nomenclature based on clinical severity and genetic cause was recently proposed by OMIM.[5] The severity classifications are A (severe), B (intermediate), and C (mild). The subtypes are numbered one to six according to the genetic cause, in the following order: (1) POMT1, (2) POMT2, (3) POMGNT1, (4) FKTN, (5) FKRP, and (6) LARGE.

Most common severe types include:

 ! Name ! OMIM ! Gene ! Locus
POMT1-CDG (MDDGA1;Walker-Warburg syndrome)236670}} POMT1 9q34.13
POMT2-CDG (MDDGA2;Walker-Warburg syndrome)613150}} POMT2 14q24.3
POMGNT1-CDG (MDDGA3; muscle-eye-brain)253280}} POMGNT1 1p34.1
FKTN-CDG (MDDGA4; Fukuyama congenital muscular dystrophy)253800}} FKTN 9q31.2
FKRP-CDG (MDDGB5; MDC1C)606612}} FKRP 19q13.32
LARGE-CDG (MDDGB6; MDC1D)608840}} LARGE 22q12.3

Presentation

The specific problems produced differ according to the particular abnormal synthesis involved. Common manifestations include ataxia; seizures; retinopathy; liver disease; coagulopathies; failure to thrive (FTT); dysmorphic features (e.g., inverted nipples and subcutaneous fat pads), pericardial effusion, and hypotonia . If an MRI is obtained; cerebellar hypoplasia is a common finding.

Ocular abnormalities of CDG-Ia include: myopia, infantile esotropia, delayed visual maturation, peripheral neuropathy (PN), strabismus, nystagmus, optic disc pallor, and reduced rod function on electroretinography.[6]

Three subtypes PMM2-CDG, PMI-CDG, ALG6-CDG can cause congenital hyperinsulinism with hyperinsulinemic hypoglycemia in infancy.[7]

N-Glycosylation and known defects

A biologically very important group of carbohydrates is the asparagine (Asn)-linked, or N-linked, oligosaccharides. Their biosynthetic pathway is very complex and involves a hundred or more glycosyltransferases, glycosidases, transporters and synthases. This plethora allows for the formation of a multitude of different final oligosaccharide structures, involved in protein folding, intracellular transport/localization, protein activity, and degradation/half-life. A vast amount of carbohydrate binding molecules (lectins) depend on correct glycosylation for appropriate binding; the selectins, involved in leukocyte extravasation, is a prime example. Their binding depends on a correct fucosylation of cell surface glycoproteins. Lack thereof leads to leukocytosis and increase sensitivity to infections as seen in SLC35C1-CDG(CDG-IIc); caused by a GDP-fucose (Fuc) transporter deficiency.

All N-linked oligosaccharides originate from a common lipid-linked oligosaccharide (LLO) precursor, synthesized in the ER on a dolichol-phosphate (Dol-P) anchor. The mature LLO is transferred co-translationally to consensus sequence Asn residues in the nascent protein, and is further modified by trimming and re-building in the Golgi.

Deficiencies in the genes involved in N-linked glycosylation constitute the molecular background to most of the CDGs.

  • Type I defects involve the synthesis and transfer of the LLO
  • Type II defects impair the modification process of protein-bound oligosaccharides.

Type I

Description Disorder Product
The formation of the LLO is initiated by the synthesis of the polyisoprenyl dolichol from farnesyl, a precursor of cholesterol biosynthesis. This step involves at least three genes, DHDDS (encoding dehydrodolichyl diphosphate synthase that is a cis-prenyl transferase), DOLPP1 (a pyrophosphatase) and SRD5A3, encoding a reductase that completes the formation of dolichol. Recently, exome sequencing showed that mutations in DHDDS cause a disorder with a retinal phenotype (retinitis pigmentosa, a common finding in CDG patients.[8] Further, the intermediary reductase in this process (encoded by SRD5A3), is deficient in SRD5A3-CDG (CDG-Iq).[9]
Dol is then activated to Dol-P via the action of Dol kinase in the ER membrane. This process is defective in DOLK-CDG (CDG-Im).[10]
Consecutive N-acetylglucosamine (GlcNAc)- and mannosyltransferases use the nucleotide sugar donors UDP-GlcNAc and GDP-mannose (Man) to form a pyrophosphate-linked seven sugar glycan structure (Man5GlcNAc2-PP-Dol) on the cytoplasmatic side of the ER. Some of these steps have been found deficient in patients.
  • Deficiency in GlcNAc-1-P transferase causes DPAGT1-CDG (CDG-Ij)[11]
  • Loss of the first mannosyltransferase causes ALG1-CDG (CDG-Ik)[12]
  • Loss of the second mannosyltransferase (adds Man II and III) causes ALG2-CDG (CDG-Ii).[13]
  • Loss of the third mannosyltransferase (adds Man IV and V) causes ALG11-CDG (CDG-Ip)[14]
  • Mutations in the other genes involved in these steps (ALG13 and ALG14) are yet to be described.
 Man5GlcNAc2-PP-Dol
The M5GlcNAc2-structure is then flipped to the ER lumen, via the action of a "flippase" This is deficient in RFT1-CDG (CDG-In).[15]
Finally, three mannosyltransferases and three glucosyltransferases complete the LLO structure Glc3Man9GlcNAc2-PP-Dol using Dol-P-Man and Dol-P-glucose (Glc) as donors. There are five known defects:
  • mannosyltransferase VI deficiency causes ALG3-CDG (CDG-Id)[16]
  • mannosyltransferase VII/IX deficiency causes ALG9-CDG (CDG-IL)[17]
  • mannosyltransferase VIII deficiency causes ALG12-CDG (CDG-Ig)[18]
  • glucosyltransferase I deficiency causes ALG6-CDG (CDG-Ic)[19]
  • glucosyltransferase II deficiency causes ALG8-CDG (CDG-Ih).[20]
 Glc3Man9GlcNAc2-PP-Dol
A protein with hitherto unknown activity, MPDU-1, is required for the efficient presentation of Dol-P-Man and Dol-P-Glc. Its deficiency causes MPDU1-CDG (CDG-If).[21]
The synthesis of GDP-Man is crucial for proper N-glycosylation, as it serves as donor substrate for the formation of Dol-P-Man and the initial Man5GlcNAc2-P-Dol structure. GDP-Man synthesis is linked to glycolysis via the interconversion of fructose-6-P and Man-6-P, catalyzed by phosphomannose isomerase (PMI). This step is deficient in MPI-CDG (CDG-Ib), which is the only treatable CDG-I subtype.
Man-1-P is then formed from Man-6-P, catalyzed by phosphomannomutase (PMM2), and Man-1-P serves as substrate in the GDP-Man synthesis. Mutations in PMM2 cause PMM2-CDG (CDG-Ia), the most common CDG subtype.[22]
Dol-P-Man is formed via the action of Dol-P-Man synthase, consisting of three subunits; DPM1, DPM2, and DPM3. Mutations in DPM1 causes DPM1-CDG (CDG-Ie). Mutations in DPM2 (DPM2-CDG) and DPM3 (DPM3-CDG (CDG-Io))[23] cause syndromes with a muscle phenotype resembling an a-dystroglycanopathy, possibly due to lack of Dol-P-Man required for O-mannosylation.
The final Dol-PP-bound 14mer oligosaccharides (Glc3Man9GlcNAc2-PP-Dol) are transferred to consensus Asn residues in the acceptor proteins in the ER lumen, catalyzed by the oligosaccharyltransferase(OST). The OST is composed by several subunits, including DDOST, TUSC3, MAGT1, KRTCAP2 and STT3a and -3b. Three of these genes have hithero been shown to be mutated in CDG patients, DDOST (DDOST-CDG (CDG-Ir)), TUSC3 (TUSC3-CDG) and MAGT1 (MAGT1-CDG).

Type II

The mature LLO chain is next transferred to the growing protein chain, a process catalysed by the oligosaccharyl transferase (OST) complex.

  • Once transferred to the protein chain, the oligosaccharide is trimmed by specific glycosidases. This process is vital since the lectin chaperones calnexin and calreticulin, involved in protein quality, bind to the Glc1Man9GlcNAc-structure and assure proper folding. Lack of the first glycosidase (GCS1) causes CDG-IIb.
  • Removal of the Glc residues and the first Man residue occurs in the ER.
  • The glycoprotein then travels to the Golgi, where a multitude of different structures with different biological activities are formed.
  • Mannosidase I creates a Man5GlcNAc2-structure on the protein, but note that this has a different structure than the one made on LLO.
  • Next, a GlcNAc residue forms GlcNAc1Man5GlcNAc2, the substrate for a-mannosidase II (aManII).
  • aManII then removes two Man residues, creating the substrate for GlcNAc transferase II, which adds a GlcNAc to the second Man branch. This structure serves as substrate for additional galactosylation, fucosylation and sialylation reactions. Additionally, substitution with more GlcNAc residues can yield tri- and tetra-antennary molecules.

Not all structures are fully modified, some remain as high-mannose structures, others as hybrids (one unmodified Man branch and one modified), but the majority become fully modified complex type oligosaccharides.

In addition to glycosidase I, mutations have been found:

  • in MGAT2, in GlcNAc transferase II (CDG-IIa)
  • in SLC35C1, the GDP-Fuc transporter (CDG-IIc)
  • in B4GALT1, a galactosyltransferase (CDG-IId)
  • in COG7, the conserved oligomeric Golgi complex-7 (CDG-IIe)
  • in SLC35A1, the CMP-sialic acid (NeuAc) transporter (CDG-IIf)

However, the use of >100 genes in this process, presumably means that many more defects are to be found.

Diagnosis

{{Empty section|date=December 2017}}

Treatment

No treatment is available for most of these disorders. Mannose supplementation relieves the symptoms in PMI-CDG for the most part,[24] even though the hepatic fibrosis may persist.[25] Fucose supplementation has had a partial effect on some SLC35C1-CDG patients.[26]

History

The first CDG patients (twin sisters) were described in 1980 by Jaeken et al.[27] Their main features were psychomotor retardation, cerebral and cerebellar atrophy and fluctuating hormone levels (e.g.prolactin, FSH and GH). During the next 15 years the underlying defect remained unknown but since the plasmaprotein transferrin was underglycosylated (as shown by e.g. isoelectric focusing), the new syndrome was named carbohydrate-deficient glycoprotein syndrome (CDGS)[28] Its "classical" phenotype included psychomotor retardation, ataxia, strabismus, anomalies (fat pads and inverted nipples) and coagulopathy.

In 1994, a new phenotype was described and named CDGS-II.[29] In 1995, Van Schaftingen and Jaeken showed that CDGS-I (now PMM2-CDG) was caused by the deficiency of the enzyme phosphomannomutase. This enzyme is responsible for the interconversion of mannose-6-phosphate and mannose-1-phosphate, and its deficiency leads to a shortage in GDP-mannose and dolichol (Dol)-mannose (Man), two donors required for the synthesis of the lipid-linked oligosaccharide precursor of N-linked glycosylation.

In 1998, Niehues described a new CDG syndrome, MPI-CDG, which is caused by mutations in the enzyme metabolically upstream of PMM2, phosphomannose isomerase (PMI).[30] A functional therapy for MPI-CDG, alimentary mannose was also described.

The characterization of new defects took increased and several new Type I and Type II defects were delineated.[31]

In 2012, Need described the first case of a congenital disorder of deglycosylation, NGLY1 deficiency.[32] A 2014 study of NGLY1 deficient patients found similarities with traditional congenital disorders of glycosylation.[33]

See also

  • Inborn error of metabolism
  • Leukocyte adhesion deficiency
  • PMM2 deficiency

References

1. ^{{cite journal | vauthors = Freeze HH, Eklund EA, Ng BG, Patterson MC | title = Neurology of inherited glycosylation disorders | journal = The Lancet. Neurology | volume = 11 | issue = 5 | pages = 453–66 | date = May 2012 | pmid = 22516080 | doi = 10.1016/S1474-4422(12)70040-6 | pmc = 3625645 }}
2. ^Jaeken, J., Hennet, T., Matthijs, G., and Freeze, H.H. (2009) CDG nomenclature: time for a change! Biochim Biophys Acta. 1792, 825-6.
3. ^Wu, X., Steet, R.A., Bohorov, O., Bakker, J., Newell, J., Krieger, M., Spaapen, L., Kornfeld, S., and Freeze, H.H. Mutation of the COG complex subunit gene COG7 causes a lethal congenital disorder. (2004) Nat. Med. 10, 518-23.
4. ^{{cite journal | vauthors = Kornak U, Reynders E, Dimopoulou A, van Reeuwijk J, Fischer B, Rajab A, Budde B, Nürnberg P, Foulquier F, Lefeber D, Urban Z, Gruenewald S, Annaert W, Brunner HG, van Bokhoven H, Wevers R, Morava E, Matthijs G, Van Maldergem L, Mundlos S | title = Impaired glycosylation and cutis laxa caused by mutations in the vesicular H+-ATPase subunit ATP6V0A2 | journal = Nature Genetics | volume = 40 | issue = 1 | pages = 32–4 | date = January 2008 | pmid = 18157129 | doi = 10.1038/ng.2007.45 }}
5. ^{{cite journal | vauthors = Amberger J, Bocchini C, Hamosh A | title = A new face and new challenges for Online Mendelian Inheritance in Man (OMIM®) | journal = Human Mutation | volume = 32 | issue = 5 | pages = 564–7 | date = May 2011 | pmid = 21472891 | doi = 10.1002/humu.21466 }}
6. ^{{cite journal | vauthors = Jensen H, Kjaergaard S, Klie F, Moller HU | title = Ophthalmic manifestations of congenital disorder of glycosylation type 1a | journal = Ophthalmic Genetics | volume = 24 | issue = 2 | pages = 81–8 | date = June 2003 | pmid = 12789572 | doi = 10.1076/opge.24.2.81.13994 }}
7. ^{{cite journal | vauthors = Sun L, Eklund EA, Chung WK, Wang C, Cohen J, Freeze HH | title = Congenital disorder of glycosylation id presenting with hyperinsulinemic hypoglycemia and islet cell hyperplasia | journal = The Journal of Clinical Endocrinology and Metabolism | volume = 90 | issue = 7 | pages = 4371–5 | date = July 2005 | pmid = 15840742 | doi = 10.1210/jc.2005-0250 }}
8. ^{{cite journal | vauthors = Züchner S, Dallman J, Wen R, Beecham G, Naj A, Farooq A, Kohli MA, Whitehead PL, Hulme W, Konidari I, Edwards YJ, Cai G, Peter I, Seo D, Buxbaum JD, Haines JL, Blanton S, Young J, Alfonso E, Vance JM, Lam BL, Peričak-Vance MA | title = Whole-exome sequencing links a variant in DHDDS to retinitis pigmentosa | journal = American Journal of Human Genetics | volume = 88 | issue = 2 | pages = 201–6 | date = February 2011 | pmid = 21295283 | doi = 10.1016/j.ajhg.2011.01.001 | pmc=3035708}}
9. ^{{cite journal | vauthors = Cantagrel V, Lefeber DJ, Ng BG, Guan Z, Silhavy JL, Bielas SL, Lehle L, Hombauer H, Adamowicz M, Swiezewska E, De Brouwer AP, Blümel P, Sykut-Cegielska J, Houliston S, Swistun D, Ali BR, Dobyns WB, Babovic-Vuksanovic D, van Bokhoven H, Wevers RA, Raetz CR, Freeze HH, Morava E, Al-Gazali L, Gleeson JG | title = SRD5A3 is required for converting polyprenol to dolichol and is mutated in a congenital glycosylation disorder | journal = Cell | volume = 142 | issue = 2 | pages = 203–17 | year = 2010 | pmid = 20637498 | pmc = 2940322 | doi = 10.1016/j.cell.2010.06.001 }}
10. ^{{cite journal | vauthors = Kranz C, Jungeblut C, Denecke J, Erlekotte A, Sohlbach C, Debus V, Kehl HG, Harms E, Reith A, Reichel S, Grobe H, Hammersen G, Schwarzer U, Marquardt T | title = A defect in dolichol phosphate biosynthesis causes a new inherited disorder with death in early infancy | journal = American Journal of Human Genetics | volume = 80 | issue = 3 | pages = 433–40 | date = March 2007 | pmid = 17273964 | pmc = 1821118 | doi = 10.1086/512130 }}
11. ^{{cite journal | vauthors = Wu X, Rush JS, Karaoglu D, Krasnewich D, Lubinsky MS, Waechter CJ, Gilmore R, Freeze HH | title = Deficiency of UDP-GlcNAc:Dolichol Phosphate N-Acetylglucosamine-1 Phosphate Transferase (DPAGT1) causes a novel congenital disorder of Glycosylation Type Ij | journal = Human Mutation | volume = 22 | issue = 2 | pages = 144–50 | date = August 2003 | pmid = 12872255 | doi = 10.1002/humu.10239 }}
12. ^{{cite journal | vauthors = Grubenmann CE, Frank CG, Hülsmeier AJ, Schollen E, Matthijs G, Mayatepek E, Berger EG, Aebi M, Hennet T | title = Deficiency of the first mannosylation step in the N-glycosylation pathway causes congenital disorder of glycosylation type Ik | journal = Human Molecular Genetics | volume = 13 | issue = 5 | pages = 535–42 | date = March 2004 | pmid = 14709599 | doi = 10.1093/hmg/ddh050 }}
13. ^{{cite journal | vauthors = Thiel C, Schwarz M, Peng J, Grzmil M, Hasilik M, Braulke T, Kohlschütter A, von Figura K, Lehle L, Körner C | title = A new type of congenital disorders of glycosylation (CDG-Ii) provides new insights into the early steps of dolichol-linked oligosaccharide biosynthesis | journal = The Journal of Biological Chemistry | volume = 278 | issue = 25 | pages = 22498–505 | date = June 2003 | pmid = 12684507 | doi = 10.1074/jbc.m302850200 }}
14. ^{{cite journal | vauthors = Rind N, Schmeiser V, Thiel C, Absmanner B, Lübbehusen J, Hocks J, Apeshiotis N, Wilichowski E, Lehle L, Körner C | title = A severe human metabolic disease caused by deficiency of the endoplasmatic mannosyltransferase hALG11 leads to congenital disorder of glycosylation-Ip | journal = Human Molecular Genetics | volume = 19 | issue = 8 | pages = 1413–24 | date = April 2010 | pmid = 20080937 | doi = 10.1093/hmg/ddq016 }}
15. ^{{cite journal | vauthors = Vleugels W, Haeuptle MA, Ng BG, Michalski JC, Battini R, Dionisi-Vici C, Ludman MD, Jaeken J, Foulquier F, Freeze HH, Matthijs G, Hennet T | title = RFT1 deficiency in three novel CDG patients | journal = Human Mutation | volume = 30 | issue = 10 | pages = 1428–34 | date = October 2009 | pmid = 19701946 | doi = 10.1002/humu.21085 | pmc=3869400}}
16. ^{{cite journal | vauthors = Körner C, Knauer R, Stephani U, Marquardt T, Lehle L, von Figura K | title = Carbohydrate deficient glycoprotein syndrome type IV: deficiency of dolichyl-P-Man:Man(5)GlcNAc(2)-PP-dolichyl mannosyltransferase | journal = The EMBO Journal | volume = 18 | issue = 23 | pages = 6816–22 | date = December 1999 | pmid = 10581255 | doi = 10.1093/emboj/18.23.6816 | pmc=1171744}}
17. ^{{cite journal | vauthors = Frank CG, Grubenmann CE, Eyaid W, Berger EG, Aebi M, Hennet T | title = Identification and functional analysis of a defect in the human ALG9 gene: definition of congenital disorder of glycosylation type IL | journal = American Journal of Human Genetics | volume = 75 | issue = 1 | pages = 146–50 | date = July 2004 | pmid = 15148656 | pmc = 1181998 | doi = 10.1086/422367 }}
18. ^{{cite journal | vauthors = Chantret I, Dupré T, Delenda C, Bucher S, Dancourt J, Barnier A, Charollais A, Heron D, Bader-Meunier B, Danos O, Seta N, Durand G, Oriol R, Codogno P, Moore SE | title = Congenital disorders of glycosylation type Ig is defined by a deficiency in dolichyl-P-mannose:Man7GlcNAc2-PP-dolichyl mannosyltransferase | journal = The Journal of Biological Chemistry | volume = 277 | issue = 28 | pages = 25815–22 | date = July 2002 | pmid = 11983712 | doi = 10.1074/jbc.m203285200 }}
19. ^{{cite journal | vauthors = Körner C, Knauer R, Holzbach U, Hanefeld F, Lehle L, von Figura K | title = Carbohydrate-deficient glycoprotein syndrome type V: deficiency of dolichyl-P-Glc:Man9GlcNAc2-PP-dolichyl glucosyltransferase | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 95 | issue = 22 | pages = 13200–5 | year = 1998 | pmid = 9789065 | pmc = 23759 | doi = 10.1073/pnas.95.22.13200| url = }}
20. ^{{cite journal | vauthors = Chantret I, Dancourt J, Dupré T, Delenda C, Bucher S, Vuillaumier-Barrot S, Ogier de Baulny H, Peletan C, Danos O, Seta N, Durand G, Oriol R, Codogno P, Moore SE | title = A deficiency in dolichyl-P-glucose:Glc1Man9GlcNAc2-PP-dolichyl alpha3-glucosyltransferase defines a new subtype of congenital disorders of glycosylation | journal = The Journal of Biological Chemistry | volume = 278 | issue = 11 | pages = 9962–71 | date = March 2003 | pmid = 12480927 | doi = 10.1074/jbc.m211950200 }}
21. ^{{cite journal | vauthors = Kranz C, Denecke J, Lehrman MA, Ray S, Kienz P, Kreissel G, Sagi D, Peter-Katalinic J, Freeze HH, Schmid T, Jackowski-Dohrmann S, Harms E, Marquardt T | title = A mutation in the human MPDU1 gene causes congenital disorder of glycosylation type If (CDG-If) | journal = The Journal of Clinical Investigation | volume = 108 | issue = 11 | pages = 1613–9 | year = 2001 | pmid = 11733556 | pmc = 200991 | doi = 10.1172/JCI13635 }}
22. ^{{cite journal | vauthors = Matthijs G, Schollen E, Pardon E, Veiga-Da-Cunha M, Jaeken J, Cassiman JJ, Van Schaftingen E | title = Mutations in PMM2, a phosphomannomutase gene on chromosome 16p13, in carbohydrate-deficient glycoprotein type I syndrome (Jaeken syndrome) | journal = Nature Genetics | volume = 16 | issue = 1 | pages = 88–92 | date = May 1997 | pmid = 9140401 | doi = 10.1038/ng0597-88 }}
23. ^{{cite journal | vauthors = Lefeber DJ, Schönberger J, Morava E, Guillard M, Huyben KM, Verrijp K, Grafakou O, Evangeliou A, Preijers FW, Manta P, Yildiz J, Grünewald S, Spilioti M, van den Elzen C, Klein D, Hess D, Ashida H, Hofsteenge J, Maeda Y, van den Heuvel L, Lammens M, Lehle L, Wevers RA | title = Deficiency of Dol-P-Man synthase subunit DPM3 bridges the congenital disorders of glycosylation with the dystroglycanopathies | journal = American Journal of Human Genetics | volume = 85 | issue = 1 | pages = 76–86 | date = July 2009 | pmid = 19576565 | pmc = 2706967 | doi = 10.1016/j.ajhg.2009.06.006 }}
24. ^{{cite journal | vauthors = Mention K, Lacaille F, Valayannopoulos V, Romano S, Kuster A, Cretz M, Zaidan H, Galmiche L, Jaubert F, de Keyzer Y, Seta N, de Lonlay P | title = Development of liver disease despite mannose treatment in two patients with CDG-Ib | journal = Molecular Genetics and Metabolism | volume = 93 | issue = 1 | pages = 40–3 | year = 2008 | pmid = 17945525 | doi = 10.1016/j.ymgme.2007.08.126 | url = }}
25. ^{{cite journal | vauthors = Westphal V, Kjaergaard S, Davis JA, Peterson SM, Skovby F, Freeze HH | title = Genetic and metabolic analysis of the first adult with congenital disorder of glycosylation type Ib: long-term outcome and effects of mannose supplementation | journal = Molecular Genetics and Metabolism | volume = 73 | issue = 1 | pages = 77–85 | year = 2001 | pmid = 11350186 | doi = 10.1006/mgme.2001.3161 | url = }}
26. ^{{cite journal | vauthors = Eklund EA, Freeze HH | title = The congenital disorders of glycosylation: a multifaceted group of syndromes | journal = NeuroRx | volume = 3 | issue = 2 | pages = 254–63 | year = 2006 | pmid = 16554263 | pmc = 3593443 | doi = 10.1016/j.nurx.2006.01.012 | url = }}
27. ^Jaeken, J., Vanderschueren-Lodeweyckx, M., Casaer, P., Snoeck, L., Corbeel, L., Eggermont, E., and Eeckels, R. (1980) Pediatr Res 14, 179
28. ^{{cite journal | vauthors = Jaeken J, Carchon H | title = The carbohydrate-deficient glycoprotein syndromes: an overview | journal = Journal of Inherited Metabolic Disease | volume = 16 | issue = 5 | pages = 813–20 | year = 1993 | pmid = 8295395 | doi = 10.1007/bf00714272| url = }}
29. ^{{cite journal | vauthors = Jaeken J, Schachter H, Carchon H, De Cock P, Coddeville B, Spik G | title = Carbohydrate deficient glycoprotein syndrome type II: a deficiency in Golgi localised N-acetyl-glucosaminyltransferase II | journal = Archives of Disease in Childhood | volume = 71 | issue = 2 | pages = 123–7 | year = 1994 | pmid = 7944531 | pmc = 1029941 | doi = 10.1136/adc.71.2.123| url = }}
30. ^{{cite journal | vauthors = Niehues R, Hasilik M, Alton G, Körner C, Schiebe-Sukumar M, Koch HG, Zimmer KP, Wu R, Harms E, Reiter K, von Figura K, Freeze HH, Harms HK, Marquardt T | title = Carbohydrate-deficient glycoprotein syndrome type Ib. Phosphomannose isomerase deficiency and mannose therapy | journal = The Journal of Clinical Investigation | volume = 101 | issue = 7 | pages = 1414–20 | year = 1998 | pmid = 9525984 | pmc = 508719 | doi = 10.1172/JCI2350 | url = }}
31. ^{{cite journal | vauthors = Haeuptle MA, Hennet T | title = Congenital disorders of glycosylation: an update on defects affecting the biosynthesis of dolichol-linked oligosaccharides | journal = Human Mutation | volume = 30 | issue = 12 | pages = 1628–41 | year = 2009 | pmid = 19862844 | doi = 10.1002/humu.21126 | url = }}
32. ^{{cite journal | vauthors = Need AC, Shashi V, Hitomi Y, Schoch K, Shianna KV, McDonald MT, Meisler MH, Goldstein DB | title = Clinical application of exome sequencing in undiagnosed genetic conditions | journal = Journal of Medical Genetics | volume = 49 | issue = 6 | pages = 353–61 | date = June 2012 | pmid = 22581936 | pmc = 3375064 | doi = 10.1136/jmedgenet-2012-100819 }}
33. ^{{cite journal | vauthors = Enns GM, Shashi V, Bainbridge M, Gambello MJ, Zahir FR, Bast T, Crimian R, Schoch K, Platt J, Cox R, Bernstein JA, Scavina M, Walter RS, Bibb A, Jones M, Hegde M, Graham BH, Need AC, Oviedo A, Schaaf CP, Boyle S, Butte AJ, Chen R, Chen R, Clark MJ, Haraksingh R, Cowan TM, He P, Langlois S, Zoghbi HY, Snyder M, Gibbs RA, Freeze HH, Goldstein DB | display-authors = 6 | title = Mutations in NGLY1 cause an inherited disorder of the endoplasmic reticulum-associated degradation pathway | journal = Genetics in Medicine | volume = 16 | issue = 10 | pages = 751–8 | date = October 2014 | pmid = 24651605 | pmc = 4243708 | doi = 10.1038/gim.2014.22 }}

External links

{{Medical resources
| DiseasesDB = 2012
| ICD10 = {{ICD10|E|77|8|e|70}}
| ICD9 = {{ICD9|271.8}}
| ICDO =
| OMIM = 212065
| OMIM_mult = {{OMIM2|212066}}
| MedlinePlus =
| eMedicineSubj =
| eMedicineTopic =
| MeshID =
}}
  • [https://www.ncbi.nlm.nih.gov/books/NBK1110/ GeneReviews/NIH/NCBI/UW entry on PMM2-CDG (CDG-Ia)Carbohydrate-Deficient Glycoprotein Syndrome, Type 1a; Congenital Disorder of Glycosylation Type 1a; Jaeken Syndrome]
  • [https://www.ncbi.nlm.nih.gov/omim/212065,601785 OMIM entries on Carbohydrate-Deficient Glycoprotein Syndrome, Type 1a; Congenital Disorder of Glycosylation Type 1a; Jaeken Syndrome]
  • [https://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=cdg GeneReviews/NIH/NCBI/UW entry on Congenital Disorders of Glycosylation Overview]
{{Inborn errors of carbohydrate metabolism}}{{Glycoproteinoses}}{{Membrane transport protein disorders}}{{Inherited disorders of trafficking}}{{DEFAULTSORT:Congenital Disorder Of Glycosylation}}

3 : Inborn errors of metabolism|Glycoprotein metabolism disorders|Membrane transport protein disorders
随便看

　

开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。

　

Copyright © 2023 OENC.NET All Rights Reserved
京ICP备2021023879号 更新时间：2024/11/12 11:56:41